Select your country
Websites worldwide
Select a country to go to the website of the respective STADA sales company.
Australia (2)
Belarus (1)
Belgium (1)
Bosnia-Herzegovina (1)
Bulgaria (1)
China (1)
Croatia (1)
Czech Republic (2)
Denmark (1)
France (1)
Hungary (1)
Ireland (1)
Italy (1)
Montenegro (1)
Netherlands (2)
Poland (1)
Portugal (1)
Romania (1)
Saudi Arabia (1)
Serbia (1)
Slovakia (1)
Slovenia (1)
Spain (1)
Switzerland (1)
Thailand (1)
The Phillippines (1)
United Arab Emirates (1)
United Kingdom (3)
Half-year results 2021
Calliditas Therapeutics and STADA partner to register and commercialize specialty therapy for IgA Nephropathy in Europe
Enzymatica has licensed to STADA exclusive rights to market and sell ViruProtect® (distributed by Enzymatica as ColdZyme®) in Vietnam.
STADA enters the cannabis market - More acceptance for "therapy that is still stigmatised".
Experienced life sciences executive Bryan Kim will join STADA from 1st April 2021.
In October, STADA acquired the rights to a triple combination product with the active ingredients levodopa, carbidopa and entacapone.